Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Feb;52(2):90-3.
doi: 10.1007/BF00308314.

Long- and short-term side effects and safety of calcitonin in man: a prospective study

Affiliations
Clinical Trial

Long- and short-term side effects and safety of calcitonin in man: a prospective study

S J Wimalawansa. Calcif Tissue Int. 1993 Feb.

Abstract

Forty-three patients were treated for a total duration of 301 patient-years with calcitonin (CT) (range 3-16 years, median duration 6 years 6 months). Eighty-four percent of patients were suffering from complications associated with Paget's disease and the remainder from osteoporosis. In the majority of patients, CT was administered by the subcutaneous route and one patient was psychologically dependent on calcitonin injections. There were no long-term side effects associated with CT therapy. In a separate group of 105 patients consisting of 83 patients on human CT and 22 patients on salmon CT, injections showed short-term side effects in 77% and 64% of these patients, respectively (NS). Side effects associated with nasally administered salmon CT in 25 patients were mild and of low incidence (32%). Long-term administration of calcitonin in humans is safe and devoid of any serious or long-term side effects.

PubMed Disclaimer

References

    1. Lancet. 1986 Mar 15;1(8481):615-6 - PubMed
    1. Lancet. 1989 Nov 18;2(8673):1180-2 - PubMed
    1. Calcif Tissue Int. 1986 Jan;38(1):3-8 - PubMed
    1. J Pharmacol Exp Ther. 1979 Jun;209(3):422-8 - PubMed
    1. Clin Endocrinol (Oxf). 1989 Apr;30(4):435-42 - PubMed

LinkOut - more resources